The CREAD (Cognitive Reserve and Alzheimer's Disease) program was a Phase 3 clinical trial program evaluating crenezumab, a monoclonal antibody designed to bind multiple forms of amyloid-beta, for the treatment of early Alzheimer's disease. The program consisted of two identical Phase 3 trials—CREAD (NCT02670083) and CREAD2 (NCT02770073)—designed to evaluate whether early intervention with this unique antibody could slow cognitive decline in patients with prodromal to mild AD[@crenezumab2020][@antiamyloid2019].
Crenezumab represented a distinct approach among anti-amyloid antibodies due to its ability to bind both soluble oligomers and fibrillar plaques, potentially offering broader protection against amyloid toxicity than antibodies that target only one form. The antibody's IgG4 isotype was selected to reduce Fc effector function, potentially improving safety while maintaining therapeutic binding[@genentech2019][@sehgal2023].
The CREAD trials were terminated in 2019 based on futility analysis, making crenezumab one of the earliest anti-amyloid programs to fail in Phase 3. Despite its negative results, the CREAD program provided important insights into early intervention, multi-target antibody design, and the challenges of amyloid-targeting therapies[@gauthier2022].
The amyloid cascade hypothesis posits that accumulation of amyloid-beta peptide in the brain is the primary trigger of Alzheimer's disease pathology, leading to downstream tau pathology, synaptic loss, and cognitive decline[@selkoe2016]. This hypothesis has been the dominant framework for AD therapeutic development for over three decades, leading to numerous anti-amyloid antibody programs.
Anti-amyloid antibodies can be categorized by their binding selectivity[@vandenberghe2023][@chen2023]:
| Antibody | Target Preference | Mechanism |
|---|---|---|
| Solanezumab | Monomers | Peripheral sink, monomer clearance |
| Crenezumab | Oligomers + plaques | Multi-target neutralization |
| Lecanemab | Protofibrils | Selective oligomer clearance |
| Donanemab | Pyroglutamate plaques | Plaque-specific targeting |
| Gantenerumab | Aggregated Aβ | Broad plaque engagement |
Crenezumab's multi-target approach was theoretically advantageous because soluble Aβ oligomers are considered the most toxic species, while existing plaques represent a reservoir of toxic oligomers that can be released over time[@antiamyloid2019][@mihalopoulos2023].
A fundamental principle underlying the CREAD program was the recognition that Alzheimer's disease begins decades before clinical symptoms appear. By the time patients present with mild cognitive impairment or mild dementia, significant neurodegeneration has already occurred[@blennow2023]. The CREAD trials specifically enrolled patients in the prodromal to mild AD stages, reflecting the hypothesis that earlier intervention might be more effective[@crenezumab2020].
This approach aligned with other prevention and early-intervention trials including the DIAN, API, and A4 studies, all targeting amyloid-positive individuals before or shortly after symptom onset[@bateman2017].
Crenezumab employs a unique multi-target approach that distinguishes it from other anti-amyloid antibodies in development[@antiamyloid2019][@sehgal2023]:
This binding profile was achieved through antibody engineering to recognize a conformational epitope present on aggregated but not monomeric Aβ. The antibody was designed to neutralize toxic oligomers while also engaging existing plaques[@fleisher2019].
Crenezumab binds to soluble Aβ oligomers, preventing their interaction with neurons and synapses[@antiamyloid2019]:
The antibody also binds to fibrillar plaques, potentially:
Despite its IgG4 isotype (reduced Fc effector function), crenezumab can still trigger:
| Feature | Crenezumab | Comparison |
|---|---|---|
| Binding | Multi-specific (oligomers + plaques) | Solanezumab (monomers), BAN2401 (protofibrils) |
| Isotype | IgG4 (reduced Fc effector) | Most others use IgG1 |
| Plaque Engagement | Yes | Some antibodies avoid plaques |
| Brain Penetration | Moderate | Varies by antibody |
The IgG4 isotype was chosen to reduce the risk of amyloid-related imaging abnormalities (ARIA), particularly ARIA-E (amyloid-related edema), which had been problematic for earlier IgG1 antibodies[@lacorte2022].
| Attribute | CREAD | CREAD2 |
|---|---|---|
| NCT Number | NCT02670083 | NCT02770073 |
| Phase | Phase 3 | Phase 3 |
| Status | Terminated (futility) | Terminated (futility) |
| Sponsor | Genentech/Roche | Genentech/Roche |
| Start Date | 2016 | 2016 |
| Termination | March 2019 | March 2019 |
| Enrollment | ~800 patients | ~800 patients |
The trials enrolled patients meeting the following criteria[@crenezumab2020][@fleisher2019]:
Inclusion Criteria:
Exclusion Criteria:
The dosing regimen was informed by Phase 2 results showing biomarker engagement at these dose levels[@fleisher2019].
Primary Endpoint:
Secondary Endpoints:
Before the Phase 3 CREAD program, crenezumab showed promise in Phase 2 studies[@fleisher2019]:
The Phase 2 results supported advancement to Phase 3 while highlighting the need for higher doses and earlier intervention.
Both CREAD trials were terminated in March 2019 based on futility analysis[@genentech2019][@crenezumab2020]:
The primary analysis showed[@crenezumab2020][@gauthier2022]:
Due to early termination, comprehensive biomarker data was limited[@gauthier2022][@galasko2023]:
The biomarker engagement, while present, was less robust than observed with successful anti-amyloid antibodies like lecanemab and donanemab.
Crenezumab's safety profile was notable for its favorable tolerability[@lacorte2022][@crenezumab2020]:
| Adverse Event | Crenezumab | Placebo |
|---|---|---|
| ARIA-E (edema) | Low incidence (<5%) | <1% |
| ARIA-H (hemorrhages) | Manageable | - |
| Infusion/injection reactions | Rare | - |
| General AE rates | Comparable to placebo | - |
The IgG4 isotype appeared to reduce ARIA rates compared to IgG1 antibodies like gantenerumab and aducanumab.
Despite negative results, the CREAD trials provided important insights for the field[@gauthier2022][@antiamyloid2019]:
Even with an antibody targeting multiple Aβ species and enrolling patients in the prodromal to mild stages, clinical benefit was not achieved. This suggests:
The doses used in CREAD may have been suboptimal:
Biomarker-confirmed amyloid pathology alone may not be sufficient:
The multi-target approach of crenezumab did not translate to superior efficacy:
| Feature | Crenezumab (CREAD) | Gantenerumab (GRADUATE) | Lecanemab (CLARITY) | Donanemab (TRAILBLAZER) |
|---|---|---|---|---|
| Target | Oligomers + plaques | Aggregated Aβ | Protofibrils | Pyroglutamate plaques |
| Isotype | IgG4 | IgG1 | IgG1 | IgG1 |
| Administration | SC monthly | SC q2w | IV q2w | IV q4w |
| Dose | 300 mg | 510 mg | 10 mg/kg | 350 mg |
| Amyloid reduction | Modest | ~50% | ~80% | ~70% |
| Clinical benefit | No | No | Yes (27%) | Yes (35%) |
| ARIA-E rate | Low | 24.9% | 12.6% | ~24% |
| Status | Terminated | Terminated | Approved | Approved |
Several factors likely contributed to the lack of efficacy[@gauthier2022][@chen2023]:
The CREAD results informed subsequent anti-amyloid development[@musiek2023][@reim2023]:
An open-label extension (CREAD-OLE) provided long-term safety data for crenezumab-treated patients, though no efficacy data was collected.
Crenezumab was included in the Alzheimer's Prevention Initiative (API) study targeting autosomal dominant AD in Colombian kindred, testing whether earlier intervention could prevent cognitive decline[@cummings2023].
The CREAD failure influenced Roche's pipeline strategy:
Crenezumab development has been discontinued following the CREAD trial results. However, the antibody remains an important case study in anti-amyloid therapeutic development:
The CREAD trial results contributed to the broader understanding of anti-amyloid immunotherapy. When compared to subsequent successful trials:
| Antibody | Target | Trial | Outcome |
|---|---|---|---|
| Crenezumab | Oligomers + Plaques | CREAD | Negative |
| Solanezumab | Monomers | EXPEDITION | Negative |
| BAN2401 | Oligomers | Clarity AD | Positive |
| Donanemab | Plaques | TRAILBLAZER | Positive |
| Lecanemab | Oligomers + Plaques | Clarity AD | Positive |
The pattern emerging from these trials suggests that oligomer-targeting antibodies like BAN2401 (lecanemab) and PMN310 may offer the best balance of efficacy and safety. CREAD's multi-target approach, while conceptually appealing, may have lacked sufficient potency at the doses tested.
Crenezumab was developed by Genentech/Roche as a humanized IgG4 monoclonal antibody with unique binding properties:
The dosing strategy in CREAD was based on:
Higher doses were explored in later stages, but the trial was terminated before dose-escalation could be fully evaluated.
The CREAD experience informed several key design elements in subsequent trials:
While crenezumab development has stopped, the knowledge gained continues to inform Alzheimer's disease drug development. The focus has shifted to:
The CREAD trials, despite their negative results, provided invaluable insights into Alzheimer's disease treatment. The trial highlighted the complexity of targeting amyloid-beta and the need for sufficient drug exposure at the site of pathology. While crenezumab did not meet its primary endpoint, the trial advanced understanding of optimal antibody design, dosing strategies, and patient selection criteria for future Alzheimer's disease clinical trials.
The multi-target approach remains theoretically compelling, and ongoing research continues to explore whether combining amyloid clearance with other disease-modifying mechanisms may yield better outcomes for patients with this devastating disease.